Amgen Inc vs. Ginkgo Bioworks Holdings, Inc.
Amgen Inc (AMGN) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| AMGN | DNA | |
|---|---|---|
| Market Cap | $234.49 billion | $468.69 million |
| Revenue (TTM) | $38.09 billion | $111.86 million |
| Net Income (TTM) | $8.74 billion | $-290,803,000 |
AMGN leads on 3 of 3 size & scale factors.
Valuation
| AMGN | DNA | |
|---|---|---|
| P/E Ratio | 27.29 | — |
| Price / Book | 20.06 | 1.12 |
| Price / Sales | 6.16 | 4.19 |
DNA leads on 2 of 2 valuation factors.
Profitability
| AMGN | DNA | |
|---|---|---|
| Net Margin | 22.95% | -259.96% |
| Return on Equity | 74.80% | -69.19% |
AMGN leads on 2 of 2 profitability factors.
Dividend
| AMGN | DNA | |
|---|---|---|
| Dividend Yield | 2.29% | — |
| Payout Ratio | 62.61 | — |
AMGN and DNA split the dividend factors evenly.
Risk & Sentiment
| AMGN | DNA | |
|---|---|---|
| Short Interest | 1.66% | 18.73% |
AMGN leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, DNA overview, DNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.